Drug Search Results
More Filters [+]

Ondansetron

Alternative Names: ondansetron, zofran, eur-1025, eur1025, eur 1025, rhb-102, rhb102, rhb 102, BEKINDA, DAS-001, AD04, AD-04, zofran odt, zuplenz
Latest Update: 2024-12-19
Latest Update Note: Clinical Trial Update

Product Description

Ondansetron is one of the medications most commonly used for empiric treatment of nausea and vomiting. Ondansetron has extreme utility as an antiemetic drug, and it is effective against nausea and vomiting of various etiologies.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/29763014/)

Mechanisms of Action: 5-HT3 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous,Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Oncology Unspecified | Oncology Unspecified | Oncology Unspecified

Known Adverse Events: Headache | Constipation | Diarrhea | Long QT Syndrome | Myocardial Ischemia | Spasm | Morphine Dependence | Serotonin Syndrome | Ileus | Intestinal Obstruction | Anaphylaxis | Drug Hypersensitivity | Cardiac Arrhythmias | Abnormalities, Radiation-Induced | Skin Abnormalities | Pregnancy Outcomes | Pregnancy, Abdominal | Hypoxia

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ondansetron

Countries in Clinic: Austria, Bulgaria, Croatia, Estonia, Finland, Latvia, Poland, Sweden, United States

Active Clinical Trial Count: 5

Highest Development Phases

Phase 3: Alcoholism

Phase 2: Alzheimer Disease|Muscle Weakness|Myasthenia Gravis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ADVANCE-AD04-001

P2

Unknown Status

Alzheimer Disease

2026-12-31

DAS-001-001

P2

Recruiting

Myasthenia Gravis|Muscle Weakness

2025-07-30

2022-003532-73

P2

Active, not recruiting

Alzheimer Disease

2025-01-24

2019-000737-39

P3

Completed

Alcoholism

2022-03-18

Recent News Events